Savicell Diagnostics

Blood Test for Early Cancer Detection

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in April 2012 by Fernando Patolsky, Savicell Diagnostics operates with 1–10 employees. The company is in the Pre-Funding stage, focusing on developing its Well-Shield platform for early disease detection. In September 2021, Savicell Diagnostics highlighted high accuracy results for its liquid biopsy platform, demonstrating progress in its core technology.

Business overview

Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of diseases, primarily focusing on cancer. This technology detects and interprets differential metabolic responses to identify disease intrusion and cell malformation. The company aims to enhance adherence to routine medical screenings through patient-friendly blood tests, serving the healthcare industry within the Health Tech & Life Sciences sector.

Strategic signal

In September 2021, Savicell Diagnostics announced high accuracy results for its liquid biopsy platform. This development is significant for the medical diagnostics industry as it validates the potential of the Well-Shield technology to provide reliable early cancer detection. For investors, this signals strong progress in clinical validation and a potential pathway toward commercialization in the competitive health tech market.

Company Intelligence Q&A

What is Savicell Diagnostics' core technology?
Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, specifically focusing on cancer, by detecting and interpreting differential metabolic responses.
When was Savicell Diagnostics founded?
Savicell Diagnostics was founded in April 2012.
What was a key development for Savicell Diagnostics in September 2021?
In September 2021, Savicell Diagnostics announced high accuracy results for its liquid biopsy platform, the Well-Shield technology.
What was the focus of a news report about Savicell Diagnostics in June 2023?
In June 2023, news reports highlighted the company's blood test that identifies cancer within 5 hours, emphasizing its life-saving potential.
What strategic collaboration did Savicell Diagnostics engage in during August 2021?
In August 2021, Orgenesis announced a collaboration with Savicell Diagnostics on the ImmunoBiopsy platform.

External links